HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN BUT NOT HIRUDIN STIMULATE PLATELET-AGGREGATION IN WHOLE-BLOOD FROM ACETYLSALICYLIC-ACID TREATED HEALTHY-VOLUNTEERS

被引:27
作者
CHEN, JH [1 ]
KARLBERG, KE [1 ]
SYLVEN, C [1 ]
机构
[1] HUDDINGE UNIV HOSP, KAROLINSKA INST, DEPT MED, S-14186 HUDDINGE, SWEDEN
关键词
PLATELETS; AGGREGATION; WHOLE BLOOD; HEPARIN; ACETYLSALICYLIC ACID; RGDS;
D O I
10.1016/0049-3848(91)90135-J
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The platelet aggregatory effect of heparin was investigated with whole blood aggregometry in blood from healthy volunteers with collagen as activator. Tests were performed before and 3 hours after 0.5 g acetylsalicylic acid given perorally. Three protocols were tested. In the first experiment and before acetylsalicylic acid low doses (2.5 and 5 IU/ml) of heparin and low mocelular weight heparin (LMW-heparin) did not affect aggregation while higher doses (25 and 250 IU/ml) had an antiaggregatory effect (p < 0.0001). After acetylsalicylic acid, and with the same amount of collagen as before acetylsalicylic acid, aggregation decreased by 82 +/- 4%. Both heparin and LMW-heparin increased the aggregation (p < 0.05). In the second experiment the collagen dose was titrated to give a similar light to moderate degree of aggregation before as compared to after acetylsalicylic acid. Low doses of heparin (p < 0.01) but not hirudin increased the aggregation to the same degree before and after acetylsalicylic acid. In the third experiment the RGDS peptide (ARG-GLY-ASP-SER), a blocker of GPIIb/IIIa platelet receptor dose dependently inhibited platelet aggregation by 93 +/- 17%. With added RGDS peptide heparin still increased aggregation (p < 0.001). In conclusion, with whole blood aggregometry both heparin and LMW-heparin but not the specific thrombin inhibitor hirudin stimulated platelet aggregation before and after acetylsalicylic acid ingestion. The heparin aggregatory effect was not inhibited by the RGDS peptide implying platelet activation via non specific mechanisms. These heparin effects could be of clinical importance for the treatment of arterial thromboembolic disease.
引用
收藏
页码:319 / 329
页数:11
相关论文
共 27 条
[1]  
ADELMAN B, 1989, J LAB CLIN MED, V113, P204
[2]  
[Anonymous], 1988, LANCET, V2, P349
[3]  
[Anonymous], 1988, BRIT MED J, V296, P320
[4]   ARTERIAL THROMBOEMBOLISM IN PATIENTS RECEIVING SYSTEMIC HEPARIN THERAPY - COMPLICATION ASSOCIATED WITH HEPARIN-INDUCED THROMBOCYTOPENIA [J].
BAIRD, RA ;
CONVERY, FR .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1977, 59 (08) :1061-1064
[5]   HEPARIN-INDUCED PLATELET-AGGREGATION - DOSE-RESPONSE RELATIONSHIPS FOR A LOW-MOLECULAR-WEIGHT HEPARIN DERIVATIVE (PK-10169) AND ITS SUBFRACTIONS [J].
BRACE, LD ;
FAREED, J .
THROMBOSIS RESEARCH, 1986, 42 (06) :769-782
[6]   ELECTRONIC AGGREGOMETER - NOVEL DEVICE FOR ASSESSING PLATELET BEHAVIOR IN BLOOD [J].
CARDINAL, DC ;
FLOWER, RJ .
JOURNAL OF PHARMACOLOGICAL METHODS, 1980, 3 (02) :135-158
[7]   PLATELETS AND THROMBOLYTIC THERAPY [J].
COLLER, BS .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (01) :33-42
[8]  
DAHLBERG G, 1940, STATISTICAL METHODS
[9]  
EIKA C, 1972, SCAND J HAEMATOL, V9, P248
[10]   EFFECTS OF THROMBIN INHIBITION ON THE DEVELOPMENT OF ACUTE PLATELET-THROMBUS DEPOSITION DURING ANGIOPLASTY IN PIGS - HEPARIN VERSUS RECOMBINANT HIRUDIN, A SPECIFIC THROMBIN INHIBITOR [J].
HERAS, M ;
CHESEBRO, JH ;
PENNY, WJ ;
BAILEY, KR ;
BADIMON, L ;
FUSTER, V .
CIRCULATION, 1989, 79 (03) :657-665